Keros Therapeutics Stock Discussion

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$  Phase 2
$Supernus Pharmaceuticals (SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$  Phase 2a
$MorphoSys (MOR.US)$  Phase 2
$Nuvation Bio (NUVB.US)$  Phase 2
$ALX Oncology (ALXO.US)$  Phase 2
$BioXcel Therapeutics (BTAI.US)$  Phase 2
$Purple Biotech (PPBT.US)$  Phase 2
$Arcus Biosciences (RCUS.US)$  Phase 2
$Medicenna Therapeutics (MDNAF.US)$  Phase 2b
$Affimed NV (AFMD.US)$  Phase 2
$Barinthus Biotherapeutics (BRNS.US)$  Phase 2b...

NHP data from $Regeneron Pharmaceuticals (REGN.US)$ 's new slide deck is very relevant for the weight loss space.
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock (SRRK.US)$ and probably also $Biohaven (BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co (LLY.US)$ , $Keros Therapeutics (KROS.US)$ ...